Olympus Announces iTind™ Center of Excellence Program to Advance Minimally Invasive Treatment of Enlarged Prostate
CENTER VALLEY, Pa., Sept. 11, 2025 /PRNewswire/ -- During National Prostate Health Month in September, Olympus Corp. of the Americas is proud to announce the new iTind™ Center of Excellence (COE) Program, which is designed to enhance care, experience and outcomes for men suffering from symptoms associated with benign prostatic hyperplasia (BPH), known as enlarged prostate.
Urologists included in the iTind Center of Excellence Program achieve a required level of training with the iTind procedure, are experienced with the iTind procedure, and demonstrate a high level of commitment to caring for their BPH patients.
In its inaugural year, the iTind Center of Excellence Program welcomes three members: C. Cragin Anderson, MD, FACS, a board-certified urologist with Colorado Urology; Petar Bajic, MD, a board-certified urologist and Director of Men's Health at Glickman Urological Institute, Cleveland Clinic; and Alex M. Kandabarow, MD, a board-certified urologist with Virginia Hospital Center Health Urology – Kingstowne.
"We are thrilled to welcome these inaugural members to the iTind Center of Excellence Program," said Matt Woodward, Vice President and Regional Business Lead for Urology at Olympus. "Patients suffering from enlarged prostate need to know that there are safe and effective alternatives to medications and invasive surgeries for relieving urinary symptoms that can seriously affect their quality of life. Our relationship with these physicians is centered on excellence in patient care and experience and aimed towards improving patient outcomes in BPH treatment."
Benchmarks for achieving an iTind Center of Excellence status for a urologist treating patients with the iTind procedure include, but are not limited to:
- Completing a specialized iTind training program;
- Upholding clinical proficiency by performing a minimum number of cases annually; and
- Providing de-identified patient data showing a mean improvement score based on FDA guidance for BPH treatments.
Visit the iTind Physician Finder to find physicians who treat BPH with the iTind procedure.
About the iTind™ Procedure
Treatment of lower urinary tract symptoms secondary to BPH using the iTind procedure is straightforward and provides rapid symptom relief in the majority of patients.1,2
- The minimally invasive iTind procedure involves the placement and removal of a temporarily implanted nitinol device.
- This treatment option does not involve cutting or removing tissue and can be performed in an office or as an outpatient hospital procedure, under general or local anesthesia.
- Patients typically return home the same day and often do not require a catheter.1
For patients who prefer a non-pharmaceutical approach to treating their BPH symptoms or are not yet ready for surgery, the iTind procedure may be well suited to become a first-line treatment.1
The iTind procedure is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men age 50 and above. Implantation of the iTind device may cause pelvic discomfort, blood in urine, painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.
Visit the iTind Procedure webpage for more information.
About Olympus
At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.
Olympus Corporation of the Americas, a wholly owned subsidiary of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit olympusamerica.com.
1 Amparore, Daniele, et al. "3-Year Results Following Treatment with the Second Generation of the Temporary Implantable Nitinol Device in Men with Luts Secondary to Benign Prostatic Obstruction." Prostate Cancer and Prostatic Diseases, vol. 24, no. 2, 2020, pp. 349–357. doi.org/10.1038/s41391-020-00281-5.
2 Chughtai, Bilal, et al. "The ITIND Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial." Urology, vol. 153, 2021, pp. 270–276. doi:10.1016/j.urology.2020.12.022.
View original content to download multimedia:https://www.prnewswire.com/news-releases/olympus-announces-itind-center-of-excellence-program-to-advance-minimally-invasive-treatment-of-enlarged-prostate-302554286.html
SOURCE Olympus Corporation of the Americas